Market Research Reports and Industry Reports

Macular Edema - Pipeline Review, H2 2017

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Macular Edema - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Macular Edema - Pipeline Review, H2 2017, provides an overview of the Macular Edema (Ophthalmology) pipeline landscape.

Macular edema is swelling or fluid retention in a specialized part of the retina called the macula. Symptoms of macular edema include blurred or wavy central vision and/or colors appear changed. There are many causes of macular edema. It is frequently associated with diabetes, where damaged blood vessels in the retina begin to leak fluids, including small amounts of blood, into the retina. Other causes include retinal vein occlusion, side effects of certain medications and certain genetic disorders, such as retinoschisis or retinitis pigmentosa.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Macular Edema - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Macular Edema (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Macular Edema (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 1, 7 and 2 respectively.

Macular Edema (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Macular Edema (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Macular Edema (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Macular Edema (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Macular Edema (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Macular Edema (Ophthalmology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Macular Edema (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Macular Edema (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Macular Edema - Overview 6
Macular Edema - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Products under Development by Companies 10
Macular Edema - Therapeutics Assessment 11
Assessment by Target 11
Assessment by Mechanism of Action 13
Assessment by Route of Administration 15
Assessment by Molecule Type 17
Macular Edema - Companies Involved in Therapeutics Development 19
ActiveSite Pharmaceuticals Inc 19
Coherus BioSciences Inc 19
Lupin Ltd0
Mabion SA0
OMEICOS Therapeutics GmbH1
Promedior Inc1
Taiwan Liposome Company Ltd1
Xbrane Biopharma AB2
Macular Edema - Drug Profiles3
ACX-107 - Drug Profile3
Product Description3
Mechanism Of Action3
R&D Progress3
aflibercept biosimilar - Drug Profile4
Product Description4
Mechanism Of Action4
R&D Progress4
ASPPDC-020 - Drug Profile5
Product Description5
Mechanism Of Action5
R&D Progress5
dexamethasone sodium phosphate - Drug Profile6
Product Description6
Mechanism Of Action6
R&D Progress6
HO-10 - Drug Profile8
Product Description8
Mechanism Of Action8
R&D Progress8
OMT-28 - Drug Profile9
Product Description9
Mechanism Of Action9
R&D Progress9
PRM-167 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
ranibizumab biosimilar - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
ranibizumab biosimilar - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
ranibizumab biosimilar - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Macular Edema - Dormant Projects 36
Macular Edema - Discontinued Products 37
Macular Edema - Product Development Milestones 38
Featured News & Press Releases 38
Jul5,017: TLC to Receive Government Grant for Development of Ophthalmology Product Candidate TLC399 38
Oct 01,015: Patent Granted by SIPO for TLCs Ophthalmic Drug Delivery System 38
Jan 06,015: Government Subsidy of NT$17.6M granted for TLCs Ophthalmology Drug Phase I/II trial 39
Dec3,013: TLC receives FDA IND approval for Sustained Release Macular Disease Drug 39
Sep4,013: Patent Approval granted by USPTO for TLCs BioSeizer Platform 39
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 41
Disclaimer 42

List Of Tables

List of Tables
Number of Products under Development for Macular Edema, H2 2017 7
Number of Products under Development by Companies, H2 2017 9
Products under Development by Companies, H2 2017 10
Number of Products by Stage and Target, H2 2017 12
Number of Products by Stage and Mechanism of Action, H2 2017 14
Number of Products by Stage and Route of Administration, H2 2017 16
Number of Products by Stage and Molecule Type, H2 2017 18
Macular Edema - Pipeline by ActiveSite Pharmaceuticals Inc, H2 2017 19
Macular Edema - Pipeline by Coherus BioSciences Inc, H2 2017 19
Macular Edema - Pipeline by Lupin Ltd, H2 2017 20
Macular Edema - Pipeline by Mabion SA, H2 2017 20
Macular Edema - Pipeline by OMEICOS Therapeutics GmbH, H2 2017 21
Macular Edema - Pipeline by Promedior Inc, H2 2017 21
Macular Edema - Pipeline by Taiwan Liposome Company Ltd, H2 2017 22
Macular Edema - Pipeline by Xbrane Biopharma AB, H2 2017 22
Macular Edema - Dormant Projects, H2 2017 36
Macular Edema - Discontinued Products, H2 2017 37

EpiCast Report: Age-Related Macular Degeneration - Epidemiology Forecast to 2026

EpiCast Report: Age-Related Macular Degeneration - Epidemiology Forecast to 2026Age-related macular degeneration (AMD) is a progressive eye condition that is characterized by the gradual deterioration of the macula, which is

USD 3995View Report

Macular Edema - Pipeline Review, H2 2017

Macular Edema - Pipeline Review, H2 2017Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Macular Edema - Pipeline Review, H2 2017, provides an overview of the Macular Edema

USD 2000View Report

EpiCast Report: Macular Edema - Epidemiology Forecast to 2026

EpiCast Report: Macular Edema - Epidemiology Forecast to 2026Macular edema (ME) is a condition characterized by the thickening and swelling (edema) of the macula, which is the area of the

USD 3995View Report

Global Macular Edema and Macular Degeneration Industry Market Research Report

Based on the Macular Edema and Macular Degeneration industrial chain, this report mainly elaborate the definition, types, applications and major players of Macular Edema and Macular Degeneration market in details.

USD 2960View Report

Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)


+91 9987 2952 42

CHOOSE FORMAT

  • PDF    USD 2000
  • Site Licence    USD 4000
  • Enterprise Wide Licence    USD 6000
$ 2000

Reports Details

Published Date : Nov 2017
No. of Pages :42
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube